Oviva key facts
as of Oct 2026- Developer of a nutritional advice platform designed to stop the progression of type two diabetes and obesity-related conditions.
- Oviva is valued at approximately $210.0M as of Oct 2026 (last reported valuation).
- It has raised $333.2M; the latest was Later Stage VC ($220.0M) in Jan 2026.
- Notable investors include Innovate UK, F-Prime Capital, Temasek Holdings, Eight Roads, Partech — 23 tracked in total.
- Status: Privately Held (backing).
Oviva's last reported valuation, Sep 2021. Nothing priced has surfaced since.
- ·The complete investor list: 23 names
- ·Watch Oviva: the Monday email on marks, rounds and moves
Oviva funding rounds
No funding rounds for Oviva are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs Oviva
23+Membership and data by Private Market View
Oviva valuation
Oviva's last reported valuation was $210 million in Sep 2021. No priced round, secondary trade or fund mark has surfaced since.
Oviva investors
23 investors are on record for Oviva, including Innovate UK, F-Prime Capital, Temasek Holdings and Eight Roads. By type, the record holds 4 venture capital firms and 1 asset manager.
About Oviva
Developer of a nutritional advice platform designed to stop the progression of type two diabetes and obesity-related conditions. The company's platform equips patients with tailored nutrition advice and personalized coaching via their phones using a network of qualified consultants and technology, enabling patients with diabetes and obesity-related conditions to improve their health at lower costs than face-to-face therapy.
- Sector
- Healthcare
- HQ
- Zurich, Switzerland
- Founded
- 2013
- Employees
- 855
- Website
- oviva.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.